Jim Cramer on Insulet Corporation: “It’s Still Too Expensive Because of the GLP-1 Threat”

Insulet is the banal successful the healthcare group. It is the biggest diminution of immoderate banal successful the healthcare group, and I looked astatine it contiguous to spot if I could urge it. It’s inactive excessively costly due to the fact that of the GLP-1 threat, existential.

Photo by Adam Nowakowski connected Unsplash

Insulet Corporation (NASDAQ:PODD) develops, manufactures, and sells insulin transportation systems for radical with insulin-dependent diabetes. It offers the Omnipod platform, including the Omnipod 5 automated insulin transportation strategy and Omnipod DASH, on with the broader Omnipod Insulin Management System. Parnassus Investments stated the pursuing regarding Insulet Corporation (NASDAQ:PODD) successful its 3rd 4th 2025 capitalist letter:

Insulet Corporation (NASDAQ:PODD) is the sole shaper of a tubeless insulin pump to dainty diabetes. The institution has durable competitory advantages from its intelligence spot and proprietary accumulation processes. Insulet’s addressable marketplace has the imaginable to importantly summation if it expands from Type 1 diabetics to the larger colonisation of Type 2 diabetics.

While we admit the imaginable of PODD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years 

Disclosure: None. Follow Insider Monkey connected Google News.